Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
Aged
Aged, 80 and over
Australia
/ epidemiology
Canada
/ epidemiology
Carcinoma, Hepatocellular
/ epidemiology
Denmark
/ epidemiology
Developed Countries
/ statistics & numerical data
Humans
Incidence
Ireland
/ epidemiology
Liver
/ pathology
Liver Neoplasms
/ epidemiology
Male
Middle Aged
New Zealand
/ epidemiology
Norway
/ epidemiology
Registries
/ statistics & numerical data
Survival Analysis
Survival Rate
United Kingdom
/ epidemiology
International Cancer Benchmarking Partnership
hepatobiliary cancers
incidence trends
international variation
net survival
population-based
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
revised:
25
06
2021
received:
17
12
2020
accepted:
28
06
2021
pubmed:
31
8
2021
medline:
20
11
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
International comparison of liver cancer survival has been hampered due to varying standards and degrees for morphological verification and differences in coding practices. This article aims to compare liver cancer survival across the International Cancer Benchmarking Partnership's (ICBP) jurisdictions whilst trying to ensure that the estimates are comparable through a range of sensitivity analyses. Liver cancer incidence data from 21 jurisdictions in 7 countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom) were obtained from population-based registries for 1995-2014. Cases were categorised based on histological classification, age-groups, basis of diagnosis and calendar period. Age-standardised incidence rate (ASR) per 100 000 and net survival at 1 and 3 years after diagnosis were estimated. Liver cancer incidence rates increased over time across all ICBP jurisdictions, particularly for hepatocellular carcinoma (HCC) with the largest relative increase in the United Kingdom, increasing from 1.3 to 4.4 per 100 000 person-years between 1995 and 2014. Australia had the highest age-standardised 1-year and 3-year net survival for all liver cancers combined (48.7% and 28.1%, respectively) in the most recent calendar period, which was still true for morphologically verified tumours when making restrictions to ensure consistent coding and classification. Survival from liver cancers is poor in all countries. The incidence of HCC is increasing alongside the proportion of nonmicroscopically verified cases over time. Survival estimates for all liver tumours combined should be interpreted in this context. Care is needed to ensure that international comparisons are performed on appropriately comparable patients, with careful consideration of coding practice variations.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2020-2031Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2021 UICC.
Références
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018;391:1023-1075.
Coleman M, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data; 2011.
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23-34.
Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493-1505.
Butler J, Foot C, Bomb M, et al. The International Cancer Benchmarking Partnership: an international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. Health Policy. 2013;112:148-155.
Eden M, Harrison S, Griffin M, et al. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions. Cancer Epidemiol. 2019;58:184-192.
Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE. Histological classification of liver and intrahepatic bile duct cancers in seer registries. J Registry Manag. 2011;38(4):201-205.
Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis. 2018;50:640-646.
Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56(4):848-854.
West J, Wood H, Logan R, Quinn M, Aithal G. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94(11):1751.
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Clin Liver Dis. 2019;13(1):1.
de Ridder J, de Wilt JHW, Simmer F, Overbeek L, Lemmens V, Nagtegaal I. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget. 2016;7:55368-55376.
Perell K, Vincent M, Vainer B, et al. Development and validation of a microRNA based diagnostic assay for primary tumor site classification of liver core biopsies. Mol Oncol. 2015;9:68-77.
Bannon F, Carlo VD, Harewood R, et al. Survival trends for primary liver cancer, 1995-2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 countries (CONCORD-2). Ann Cancer Epidemiol. 2019;3(6):6-31.
Bray F, Colombet M, Mery L, et al., eds. Cancer Incidence in Five Continents, Vol. XI (Electronic Version). Lyon: International Agency for Research on Cancer; 2017.
Segi M, Fujisaku S, Kurihara M. Geographical observation on cancer mortality by selected sites on the basis of standardised death rate. Gan. 1957;48:219-225.
Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68:113-120.
Coviello E, Seppä K, Dickman PW, Pokhrel A. Estimating net survival using a life-table approach. Stata J. 2015;15:173-173.
Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78(9):2004-2010.
Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40:2307-2316.
Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2012;12(3):530.
Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. Tnm/okuda/barcelona/unos/clip international multidisciplinary classification of hepatocellular carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging. 2014;39:1070-1087.
Andersson TM-L, Rutherford MJ, Myklebust TA, et al. Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study. Br J Cancer. 2021;124:1026-1032.
ENCR. Recommendations for Coding Basis of Diagnosis; 1999. https://www.encr.eu/working-groups-and-recommendations
NAACCR. Standards for Cancer Registries, Standard Data Edits, Volume iv, Version 18c; 2019. https://www.naaccr.org/standard-data-edits/
IARC. IARC Check and Conversion Program.
International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-664.
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. Easl-eortc clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474.